Intelligence Profile
Research Papers
Key Research Papers and Clinical Trials
Recent research on gonadorelin (GnRH agonist) therapy spans several clinical applications, though detailed study methodologies and results are limited in the available evidence.
Pediatric Applications
A 2026 systematic review examined outcomes of GnRH agonist therapy in boys with central precocious puberty, focusing on final height and long-term health effects, though specific findings are not detailed in the available evidence. Additional pediatric research explored diagnostic approaches, with one study investigating the utility of basal luteinizing hormone levels for evaluating central precocious puberty.
An animal study using juvenile rats demonstrated that sustained GnRH agonism can alter endocrine dynamics and pubertal progression, providing preclinical insights into the therapy's mechanisms.
Reproductive Medicine
Several studies examined GnRH agonist applications in assisted reproduction. A 2026 retrospective cohort study investigated reproductive outcomes in patients with different adenomyosis subtypes following ultralong GnRH agonist pretreatment before frozen embryo transfer, though sample sizes and specific results are not provided. A systematic review and meta-analysis compared progestogen-primed ovarian stimulation with GnRH antagonists and/or agonists for women undergoing assisted reproduction, but detailed findings are not available.
Cancer Treatment
Research addressed GnRH agonist use in prostate cancer care, with one 2026 review examining androgen deprivation therapy and cardiovascular health implications, highlighting both challenges and opportunities in prostate cancer management.
Clinical Trials
Multiple ongoing or completed clinical trials are investigating GnRH agonist applications, including Phase 2 studies comparing luteal phase support protocols in IVF cycles and evaluating combined treatments for prostate cancer. However, specific trial designs, sample sizes, and outcomes are not detailed in the available evidence.
Limitations
The available evidence provides limited detail on study methodologies, sample sizes, and specific clinical outcomes, making comprehensive assessment of gonadorelin's efficacy and safety profile challenging based on these sources alone.